Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

The US Supreme Court rejected a case asking the justices to interpret a patent-infringement safe-harbor provision in a ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, is a company that specializes in innovative ...

HB Wealth Management LLC lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% in the ...

Zacks Research raised their FY2024 earnings per share (EPS) estimates for Edwards Lifesciences in a research note issued on ...

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...